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INTRODUCTION
Cancer and the provision of cancer care places a significant and
growing burden on patients, citizens, and economies. Europe
provides some of the best cancer care in the world and
conducts high-quality, globally recognized cancer research.
There are still significant disparities, however, in public
information about cancer, accessing cancer care, delivering
optimal treatment, supporting cancer survivorship, and
integrating cancer research and innovation across European
countries. In addition, costs of current treatments and long-
term follow-up are placing significant economic burdens on
European health care systems. Improvements in quality of
care, translation of research discoveries, and promotion of
innovation will have to be achieved within affordable eco-
nomic models.
Acknowledging these challenges, a group of European
oncology leaders have formed a partnership with cancer
patients and their representatives. The European Cancer
Concord (ECC) is a unique patient-centered partnership that
will act as a catalyst to achieve improved access to an optimal
standardofcancer careand research for Europeancitizens.The
strength of this partnership among health care professionals,
patient advocacy organizations, and patients is essential to
bring about the changes required to improve cancer-related
outcomesacrossEurope.Cost-effectivecancercareandcancer
research excellence can contribute significantly to the wealth
and health of the European citizen.
Strengthening and upholding the rights of individual cancer
patients and their families are the guiding principles of this
initiative. In order to provide tangible benefits for European
cancer patients, the ECC proposes the creation of a “European
Cancer Patient’s Bill of Rights,” a patient charter that will
underpin equitable access to an optimal standard of care
for Europe’s citizens. Three patient-centered principles
(termed “Articles”) underpin the European Cancer Patient’s
Bill of Rights:
Article 1: The right of every European citizen to receive the
most accurate information and to be proactively involved in
his/her care.
Article 2: The right of every European citizen to optimal and
timely access to appropriate specialized care, underpinned
by research and innovation.
Article 3: The right of every European citizen to receive care in
health systems that ensure improved outcomes, patient
rehabilitation, bestquality of life and affordable health care.
THE GLOBAL BURDEN OF CANCER
At a global level, the burden of cancer is rising, with incidence
projected to increase from 12.7million in 2008 to 21.4 million
in 2030 [1]. Cancer represents a significant cause of mortality
worldwide,with7.6milliondeaths in2008 [2]. In thedeveloping
world, cancer causes more deaths than HIV/AIDS, tuberculosis,
and malaria combined [3]. Morbidity and quality-of-life issues
impose an additional burden, reflected in the loss of ∼170
million healthy life-years worldwide due to cancer and its
sequelae in 2008 [4].That figure translates to a global economic
impact from premature death and disability of €895 billion,
equivalent to 1.5% of the world’s gross domestic product [5].
The Burden of Cancer in Europe
In Europe in 2012, there were an estimated 3.45 million new
cases of cancer and 1.75 million cancer deaths [6]. The aging
population will result in significant increases in absolute
numbers of cancer cases over the next 30 years [7, 8]. The
recently releasedWorld HealthOrganization report, European
Health Report 2012: Charting the Way to Well-Being, high-
lights the significant burden that cancer places on the
European citizen [9]. In 28 of the 53 countries covered by the
report, cancer has replaced cardiovascular disease as the
leading cause of premature death [9, 10]. This increasing
cancer burden will not only affect patients and their families
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but will also be a significant issue for health care systems and
for the future economic competitiveness of Europe.
Cancer in Europe: The Positives
Impressive progress in cancer control has been achieved in the
last30years,withEuropean scientists andclinicianscontributing
significantly to gold standard advances that have improved
canceroutcomesglobally.Measurable improvementshavebeen
achieved for certain cancers, including testicular, breast, ma-
lignant lymphoma, gastric, colorectal, and leukemia. Many of
these advances emphasize how pan-European collaborative
approachescanyield significantbenefits forcancerpatients [11].
In addition, public health policies on tobaccohave reduced
the incidence of lung and other tobacco-related cancers in
men, although lung cancer mortality in women will soon
surpass breast cancer in the European Union [12]. Ireland
became the first country in the world to introduce a national
ban on smoking in the workplace, catalyzing a pan-European
approach to reducing tobacco use. European scientists have
been at the forefront of innovative screening and vaccination
approaches for cervical cancer [13, 14]. Moreover, Europe has
promoted the development of meritocratic pan-national
research networks (e.g., L’Institut National du Cancer in France
[15] and the National Cancer Research Institute in the United
Kingdom [16]) and effective pan-European collaborative groups
(e.g., European Organisation for Research and Treatment of
Cancer, TransBIG, Pan-European Trials in Adjuvant Colon Cancer,
and the CONCORD study [11, 17–19]) that have supported
Europe’s leadership in large practice-changing randomized
clinical trials. Increased participation in these trials and asso-
ciated translational research studies have allowed European
patients to benefit from the latest diagnostic and therapeutic
advances; however, there are significant disparities between
Europe and the U.S. and particularly within Europe itself in
accessing optimal care and innovative cancer treatment in
a timely fashion.
Cancer in Europe: The Negatives
The recent series in The Lancet on “Health in Europe”
highlighted increasing disparities both between and within
countries in Europe [20], with cancer a prime example of this
inequality. Significant differences in cancer survival rates
persist between individual European countries and regions
[21, 22] and are linked to socioeconomic status [23, 24],
patient age [25], access to quality care [22, 23], and lack of
a comprehensive National Cancer Control Plan (NCCP). The
just-published EUROCARE-5 study, although indicating a trend
of improving survival throughout Europe, highlights significant
disparities in outcomebetweendifferent Europeannations [26].
The lackof cancer registration data inmany European countries,
combined with a significant dearth of population-based clinical
efficacy data (outside the context of clinical trials), needs to be
addressed. The current pricing of certain cancer drugs is be-
coming unsustainable, as was recently highlighted by a large
group of international experts involved in the treatment of
chronicmyeloid leukemia [27].Althoughgenetic testing is crucial
in identifyingrisk inanumberofinheritedcancers,countriessuch
as Romania have no public access to BRCA1/2 testing (A. Eniu,
Cancer Institute“I.Chiricuta”DepartmentofBreastTumors,Cluj-
Napoca, personal communication).Worrying disparities identified
at all stages of the cancer continuum (Table 1) reflect the
challenges todeliveryofeffective cancerhealth care inEurope.
A further obstacle to providing optimal treatment has been
the European Clinical Trials Directive. Its introduction in 2001
corresponded with a 25% overall reduction in the number of
clinical trials in Europe, and in certain countries, the reduction
hasbeenmorethan50%[28].Giventhesefigures, it is imperative
that the current revision of the directive [29] ensures more
effective clinical trial activity for the European cancer patient.
The two-step process for registration of new drugs—involving
both European Medicines Agency approval and, in many
countries,ahealthtechnologyassessment—alongwithavariety
of local issues (e.g., pricing negotiations, costs) can also lead to
significant differences in time to access for new therapeutic
interventions between European nations when comparedwith
the U.S. Recognizing that incremental innovation must be
pursued to foster research, a Europe-wide harmonization of
health technology assessment methods, mediated through
collaborative networks such as the European Network for
Health Technology Assessment [30], is necessary to close the
gap in access to new diagnostics and treatments (radiotherapy,
surgery, medicines, devices).
SHAPINGAPATIENT-ORIENTEDSTRATEGYFORCANCERCARE
INEUROPE:THEECCANDTHEEUROPEANCANCERPATIENT’S
BILL OF RIGHTS
Recognizing the need to address the pressing issues noted and
toplace the cancer patient at the heart of the solution [31], the
ECC has been established, comprising European oncology
leaders in a unique partnership with cancer patients, care-
givers, and their advocates (supplemental online Appendix 1).
The strength of this cooperative approach is essential to
accelerate the changes required to improve cancer-related
outcomes for all European citizens. The ECC is a patient-
centered partnership that aims to enable improved access to
public education about cancer, cancer care, cancer research,
and innovation. The ECC is dedicated to improving the
outcomes for all cancer patients in Europe by promoting
a shared understanding of the key issues in cancer awareness,
research, prevention, rapid access to appropriate specialized
treatment, care delivery, rehabilitation, and patient survivor-
ship andbymobilizingall stakeholders to implement improved
Table 1. Disparities in cancer health care in Europe
Patient-oriented cancer education
Access to information and support
National/regional cancer prevention strategies
Access to comprehensive evidence-based cancer screening
programs
Structured national/regional cancer care delivery, including
availability of new and existing diagnostics and therapies
Pricing of cancer drugs and therapies
Clearly articulated and appropriately resourced cancer
research and innovation strategies
Access to appropriate pain management
Comprehensive citizen-focused strategies on long-term
follow-up and survivorship
Provision of comprehensive and compassionate palliative/
end-of-life care
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innovation in cancer care in a cost-effective manner across
Europe.
TheECC isdedicated to improving theoutcomes forall
cancer patients in Europe by promoting a shared
understanding of the key issues in cancer awareness,
research, prevention, rapid access to appropriate
specialized treatment, care delivery, rehabilitation,
and patient survivorship and by mobilizing all stake-
holders to implement improved innovation in cancer
care in a cost-effective manner across Europe.
As part of a “Wealth is Health” strategy that empowers
European citizens, the ECC has created a European Cancer
Patient’s Bill of Rights, a charter to challenge the current in-
equalities that cancer patients in Europe experience on a daily
basis. This bill of rights defines fundamental pan-European
quality standards for provision of information, access and
delivery of cancer care and research to European citizens.
Through this patient-focused approach, the ECC enshrines the
principles of equitable access to an appropriate and earliest
possible diagnosis and a defined optimal quality of specialized
care and clinical management for every cancer patient across
Europe.Optimal cancercarenotonlycontributes to thehealthof
European citizens but also provides demonstrable economic
benefit, with earlier access to high-quality diagnosis leading to
moresuccessful therapeutic interventionandfacilitatingareturn
to more active daily living, including a return to the workplace
when relevant.
Realizing the Vision: The European Cancer Patient’s Bill
of Rights
Three patient-centered principles underpin the European
Cancer Patient’s Bill of Rights:
Article 1: The right of every European citizen to be
informed and involved in his/her care
Cancer services must be patient centered, reflecting the
views and needs of patients and their families. Individuals
may have different perceptions of their needs than health
care professionals. Good communication between health
care professionals and patients will greatly improve care and
enhance patient satisfaction. Shared decision making, in-
volving a two-way transparent process between the health
care providers and the European citizen, must be the over-
arching theme of this first principle. The full text of Article 1 is
shown in Figure 1.
Article 2: The right of every European citizen to optimal
and timely access to appropriate specialized care,
underpinned by research and innovation
Access to essential cancer services must be the right of every
European citizen, regardless of socioeconomic status, gender,
age, or nationality. Clear pathways of access to clinical
innovation and associated research activities must inform all
stages of the patient’s cancer journey. This second principle
depends on equitable and transparent access to optimal
cancer care. The full text of Article 2 is shown in Figure 2.
Article 3: The right of every European citizen to receive
care in health systems that ensure improved outcomes,
patient rehabilitation, best quality of life, and affordable
health care
Cancer care at a national levelmust beorganized in health care
systems according to an integrated, efficiently budgetedNCCP
that conforms to European guidelines and best international
practice. The NCCP should develop a cancer center/cancer
network/multidisciplinary team model that captures all
aspects of cancer care, research, and innovation, from
diagnosis through treatment and rehabilitation, including
patient survivorship and end-of-life care. A comprehensive
and holistic approach, encompassing the entire cancer care
continuum, must inform this third principle. The full text of
Article 3 is shown in Figure 3.
Advancing the Cancer Agenda in an Era of
Economic Austerity
Strengtheninghealth care systems is key todelivering strategies
that will gain traction in optimizing cancer outcomes. In
addition to the increasing health burden, the need to consider
affordability andmethods to “bend the cancer cost curve” [32]
must be addressed. Policy leaders, health care professionals,
pharmaceutical andmedical technologies industries, patients,
and patient advocacy organizations must engage construc-
tively to deliver tangible solutions. The American Society of
Clinical Oncology has “identified the rising cost of cancer care
as an opportunity to sharpen the focus on the need to ensure
high-quality care while reducing unnecessary expense for our
patients, their families, and society at large” [33]. Recently, the
InstituteofMedicine’sNational CancerPolicyForumconvened
a public workshop, “Delivering Affordable Cancer Care in the
21st Century,” to investigateways to ensure that patients have
access to high-quality, affordable cancer care in these times of
economic austerity [34]. The subsequent report, “Delivering
High-Quality Cancer Care: Charting a New Course for a System
in Crisis” [35], underscores the burgeoning challenges that
cancer presents to the U.S. health care system, particularly
whenweconsider that thepopulationaged65yearsorolder in
the U.S. will increase from ∼40 million in 2009 to nearly 90
million by 2050 [36].
In Europe, increasing cancer incidence has not been
matched by proportionate rises in cancer-related spending
within European health budgets, as is particularly evidentwith
the differences in the percentages of gross domestic product
spentonhealth care.Thereare significantdifferences in cancer
budgets across Europe [20, 37–39], particularly in cancer
health care spending in Central and Eastern Europe [37, 38],
and these differences, combinedwith the inability to provide
standard-of-care technologies in different European countries
at prices based on national purchasing power, contribute to
a lack of equity that must be addressed. A recently published
study of the economic burden of cancer in the EU-27 countries
(EU members from January 2007 through June 2013) found
major differences in spending per cancer capita between
countries [40].
Under-resourcing of cancer health care, particularly in the
context of an increasing cancer burden, will lead to increased
morbidity andmortality, spiraling associated health costs, and
significant loss of productive life-years and will negatively
www.TheOncologist.com ©AlphaMed Press 2014
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affect the health of European citizens and economies. However,
the resourcingofcancerhealth care in European countriesmust
be considered in the context of a viableNCCP [15],with a clearly
defined economic strategy, to ensure that additional spending
translates into quality care and improved outcomes for cancer
patients.
Innovation as a Key Driver of Improved Cost-Effective
Cancer Care
Theeconomicburdenofcancerworldwide is nowapproaching
€1 trillion, and theassociated lost yearsof lifeandproductivity
mean that cancer now places the largest economic drain on
the global economy of any disease in the world [5]. Cancer
diagnostics (imaging, biomarkers) and therapies (surgery,
radiation, newmedicines and devices) have led to statistically
significant increases in 1-year and 5-year survival rates and
improvements in cancer outcomes, with significant quality-
adjusted benefit achieved at a fraction of the economic cost of
increased morbidity, mortality, and loss of productive life-years
[41–46]. A clear example of this progress is breast cancer, for
whichmoreeffectivemanagementby innovativediagnosticand
therapeutic approaches has been accompanied by approxi-
mately a fivefold increase in return on investment [42, 45]. In
France, it is estimated that diagnostic and therapeutic
innovation has contributed to a significant decline in cancer
mortality rates in the period 2002–2006 [42, 44, 46].
It is important to stress, as voiced by many participants at
the recent InstituteofMedicineworkshop [34], thatdiagnostic
and therapeutic innovation can increase thevalueof improved
health andoutweigh the additional costs only if implemented
with a structured, cost-effective approach that emphasizes
measurable improvements in outcome for the cancer patient
[33, 37]. In this regard, innovative models such as L’Institut
National du Cancer’s national genomics platform support a
personalized medicine approach that delivers quality cancer
care for the patient and value for money for the health
care payer [42, 47]. Resourcing and pricing issues must be
addressed in a meaningful and transparent fashion to achieve
a just price, as highlighted in the recent article [48] and ac-
companying editorial [49] in the Journal of Clinical Oncology,
ensuring optimal value in the delivery of quality care for
patients.Theuseofcomparativeeffectiveness research tohelp
Figure 1. Article 1, European Cancer Patient’s Bill of Rights.
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pursue a strategy that balances value and cost, leading to a
quality, cost-effective solution for cancer patients, is pertinent
to this debate.Maximizing clinical trial and research activity at
the pan-European level also provides an unrivaled framework
for delivering “added value” for European patients and should
be vigorously pursued.
Our vision for improved cancer care for European
citizens, empowered by research and innovation,
aims to encourage the delivery of cost-effective,
evidence-based care that will improve outcomes for
cancer patients, consistentwith the aimsof theWorld
Cancer Declaration, which calls for significant im-
provement in global cancer survival rates by 2020.
Our vision for improved cancer care for European citizens,
empowered by research and innovation, aims to encourage the
delivery of cost-effective, evidence-based care that will improve
outcomes for cancer patients, consistent with the aims of the
World Cancer Declaration, which calls for significant improve-
ment in global cancer survival rates by 2020 [50, 51]. In the
European context, innovationas a keydriver of improvedcancer
care complements the vision of the European Partnership for
ActionAgainstCancer,which iscommittedtoreducingthecancer
burden by 15% by 2020, and is consistent with the Innovation
Union and the Europe 2020 growth strategy of the European
Union. Italsoprovidesan impetus to theCouncil of theEuropean
Union’s conclusions on “Reducing the Burden of Cancer” [52].
The European Cancer Patient’s Bill of Rights builds on other
cancer-focused initiatives, particularly the Charter of Paris [51]
but also the World Cancer Declaration of the Union for Inter-
national Cancer Control [50], the European Code Against Cancer
[53], and the “Stop Cancer Now!” campaign, launched by the
European School of Oncology following the World Oncology
Forum in Lugano, Switzerland [54]. The ECC’s commitment to
establishing a charter for cancer patients, achieved through
avibrantandequalpartnershipamonghealthcareprofessionals,
cancer patients, and their representatives and bolstered by
robust health economic principles, aims to deliver a unique
“Wealth is Health” initiative that promotes optimal cancer care
andresearch, reduces lossofproductive life-years,enablesactive
survivorship and rehabilitation, and increases health care
innovation, thus leveraging wider benefits for European citizens
and societies. The principles of equity and transparency will
Figure 2. Article 2, European Cancer Patient’s Bill of Rights.
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underpinallaspectsof theECCandtheEuropeanCancerPatient’s
Bill of Rights, culminating in the translation of health and societal
benefit directly to the European citizen.
CONCLUSION
Cancer is placing an increasing health, economic, and societal
burden on Europe’s citizens. The current disparities between
European nations at all stages of the cancer patient’s journey
are no longer acceptable. In the context of the World Cancer
Declaration and the Europe 2020 strategy, we must respond
urgently to this pressing challenge or face a major epidemic
that will have a significant impact on both the wealth and
the health of the European citizen.The ECC is actively engag-
ing with all relevant stakeholders to deliver its vision and
partnering with patients and advocacy groups, learned soci-
eties, cancer registries, industry, governmental agencies and
health care payers, the European Commission, the European
Medicines Agency, health technology assessment agencies,
cancer charities, and other key stakeholders. The principle of
inclusivitywill be actively pursued, ensuring that the European
citizen receives the maximum support and benefit from this
initiative. The vibrant engagement of health care professio-
nals and patients can help achieve progress in innovation,
research, and care to deliver improved outcomes for cancer
Figure 3. Article 3, European Cancer Patient’s Bill of Rights.
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patients in Europe.The EuropeanCancer Patient’s Bill of Rights
is a key early output, representing an important first step in
a strategy to deliver measurable benefits for European society
as a whole. Launching this bill of rights in the European
Parliament onWorldCancerDay, inpartnershipwith European
cancer patient organizations and Members of the European
Parliament Against Cancer (MEPs Against Cancer), represents
a clear commitment to promulgating and implementing this
catalyst for change for European citizens. If successful, it may
also provide a model for developing collaborative patient-
centeredapproaches todeliverequitable cancer care inother
regions throughout the world.
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